Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor rejection is observed when at least 50% of cells are MMRd. To enrich the MMRd fraction, MMRp/MMRd tumors are treated with 6-thioguanine, which leads to tumor rejection. These results suggest that genetic and pharmacological modulation of the DNA mismatch repair machinery potentiate the immunogenicity of MMR heterogeneous tumors.

Amodio, V., Lamba, S., Chilà, R., Cattaneo, C.M., Mussolin, B., Corti, G., et al. (2023). Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. CANCER CELL, 41(1), 196-209.e5 [10.1016/j.ccell.2022.12.003].

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance

Tripodo, Claudio;
2023-01-09

Abstract

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor rejection is observed when at least 50% of cells are MMRd. To enrich the MMRd fraction, MMRp/MMRd tumors are treated with 6-thioguanine, which leads to tumor rejection. These results suggest that genetic and pharmacological modulation of the DNA mismatch repair machinery potentiate the immunogenicity of MMR heterogeneous tumors.
Settore MED/08 - Anatomia Patologica
Amodio, V., Lamba, S., Chilà, R., Cattaneo, C.M., Mussolin, B., Corti, G., et al. (2023). Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. CANCER CELL, 41(1), 196-209.e5 [10.1016/j.ccell.2022.12.003].
File in questo prodotto:
File Dimensione Formato  
Genetic and pharmacological modulation of DNA Tripodo.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 3.3 MB
Formato Adobe PDF
3.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/578916
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact